Christopher Poss Email and Phone Number

Proposed and filled the first chemoinformatics position within Pfizer Medicinal Chemistry. The impact of this role led to the formation of a six-person chemoinformatics team.• Designed and developed a variety of chemoinformatic solutions for improving medicinal chemistry design effectiveness. • Co-led a team in the design and implementation of an enterprise application (Integrated Design Environment: IDE) to capture and track information relevant to design ideas. This application is in daily use across the worldwide medicinal chemistry organization.• Defined an enterprise application for medicinal chemistry design (IDE) by working within Business Technology for one year. Developed the business case, ROI, and consolidated medicinal chemistry requirements across global sites, as well as writing RFPs and overseeing the bidding process with third party vendors.• Team Leader for the development of a process to automatically capture prospective in silico model predictions (ADMET, potency), and comparative analysis of these calculations versus measured data.• Developed a FileMaker Pro application enabling the capture and discussion of new chemistry designs. Employed by 30 medicinal chemistry teams, this application was the forerunner to the enterprise Integrated Design Environment application.• Developed an automated data aggregation and analysis process (ADP) to enable medicinal chemists to focus on data analysis and compound design. This process was implemented across worldwide medicinal chemistry and is still in use today.

Director of medicinal chemistry laboratories responsible for the design and synthesis of small molecule immunological pharmaceuticals.Supervised up to 18 FTEs (6 lab heads; 12 associates).Led the discovery of three molecules that reached significant development milestones:- CCR1 antagonist: Candidate compound selected for clinical development (Multiple Sclerosis), Phase I trials completed.- JAK3 Inhibitor: Compound advanced to candidate decision.- TPO agonist: Pre-candidate identified prior to program termination.Project Coordinator for a portfolio of Exploratory Immunology chemistry projects.

Design of structurally novel back-up candidates for CCR1 antagonist program.Coordinated bulk synthesis of candidate compound for exploratory toxicology studies.Identification of prototype CCR1 antagonist candidate for clinical development. Adequate pharmacokinetics, safety, and signs of efficacy demonstrated in Phase I trials.

Design and synthesis of SH2 domain binding antagonistsDesign and synthesis of analogs of the protein trafficking inhibitor Brefeldin A.Participated in building company during its first years as a start-up.